2000
DOI: 10.1097/00001721-200006000-00005
|View full text |Cite
|
Sign up to set email alerts
|

Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins

Abstract: Tissue factor pathway inhibitor (TFPI) is released to circulating blood after intravenous and subcutaneous injections of heparins, and may thus contribute to the antithrombotic effect of heparins. A previous study suggested different abilities of various low molecular weight heparins (LMWH) to release endogenous TFPI, but the dose-response relationship was not determined. In the present study, the dose-response relationship for escalating doses of two LMWHs, dalteparin and enoxaparin, on the release of endogen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
14
0

Year Published

2000
2000
2018
2018

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 21 publications
(14 citation statements)
references
References 18 publications
0
14
0
Order By: Relevance
“…However, in a recent study from our own laboratory, direct head-to-head comparisons of different doses of two LMWHs (dalteparin and enoxaparin) failed to demonstrate any large differences in the release of TFPI by putative equivalent doses [49]. The effect on anti-factor Xa and anti-factor IIa activities were markedly different for the two species, and the differential effect on the release of TFPI may thus not explain a possible difference in antithrombotic potential between these two LMWHs.…”
Section: Introductionmentioning
confidence: 87%
See 1 more Smart Citation
“…However, in a recent study from our own laboratory, direct head-to-head comparisons of different doses of two LMWHs (dalteparin and enoxaparin) failed to demonstrate any large differences in the release of TFPI by putative equivalent doses [49]. The effect on anti-factor Xa and anti-factor IIa activities were markedly different for the two species, and the differential effect on the release of TFPI may thus not explain a possible difference in antithrombotic potential between these two LMWHs.…”
Section: Introductionmentioning
confidence: 87%
“…The release of TFPI results in a two-fold to fivefold increase in total TFPI activity [44,45], a three-fold to ten-fold increase in TFPI total antigen levels [33], and an eight-fold to fifteen-fold increase in TFPI free antigen levels [46,47]. After subcutaneous injection of either UFH or LMWH, the release is maximal after only 30-60 min as compared with the maximal anti-factor Xa and anti-factor IIa activities after 3-5 h [35, [47][48][49]. This rapid release of TFPI may involve rapid absorption of heparin fragments without anti-factor Xa and anti-factor IIa activities, but with retained ability to release TFPI.…”
Section: Introductionmentioning
confidence: 99%
“…[89][90][91] Moreover, LMWHs selectively inhibit factor Xa without affecting thrombin and may be less likely to deplete TFPI pools over time. 79,80,82,92,93 Thus, there have been several reports in which LMWHs have been successfully substituted for unfractionated heparin in managing Trousseau's syndrome. 64,94 However, it should be noted that the ability of some LMWHs to mediate some of the heparin actions indicated in Figure 1 may not be equivalent.…”
Section: Alternative Approaches To the Management Of Trousseau's Syndmentioning
confidence: 99%
“…The peak TFPI activity is reached Ϸ4 h after s.c. administration. TFPI activity is also elevated in the plasma from heparin-treated animals, albeit to a lesser extent, whereas enoxaparin (or dalteparin) resulted in a minimal increase of plasma TFPI activity (33). These results strongly suggest that the administration of rdLMWH-1 or -2 is associated with superior mobilization of TFPI from the endothelium as compared with other heparin-derived molecules.…”
Section: -O-sulfated Tetrasaccharide As An Indicator Of Anticoagulanmentioning
confidence: 76%